Departamento
HOSPITAL UNIVERSITARIO RUBER
Publicaciones (39) Publicaciones en las que ha participado algún/a investigador/a
2016
-
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
Cell, Vol. 167, Núm. 1, pp. 260-274.e22
-
A Painful Nipple: A Rare Presentation for an Infiltrating Lobular Carcinoma
Breast Journal
-
A prognostic neonatal neuroimaging scale for symptomatic congenital cytomegalovirus infection
Neonatology, Vol. 110, Núm. 4, pp. 277-285
-
Adipose mesenchymal stromal cell therapy in a desperate case of right-hand ischemia
Cytotherapy, Vol. 18, Núm. 6, pp. 725-728
-
Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel
Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390
-
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366
-
Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension
Basic Research in Cardiology, Vol. 111, Núm. 4
-
Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
Cancer and Metastasis Reviews, Vol. 35, Núm. 2, pp. 323-332
-
Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response
Annals of Surgical Oncology, Vol. 23, Núm. 12, pp. 3831-3837
-
Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention
Journal of the American College of Cardiology, Vol. 67, Núm. 23, pp. 2705-2715
-
Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer
Cancer Research, Vol. 76, Núm. 8, pp. 2301-2313
-
Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6
Trials
-
Etirinotecan pegol for the treatment of breast cancer
Expert Opinion on Pharmacotherapy, Vol. 17, Núm. 5, pp. 727-734
-
Ex vivo high-frequency ultrasound: A novel proposal for management of surgical margins in patients with non-melanoma skin cancer
Journal of the American Academy of Dermatology, Vol. 74, Núm. 6, pp. 1278-1280
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052
-
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
Oncotarget, Vol. 7, Núm. 35, pp. 56295-56308
-
Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations
Pigment Cell and Melanoma Research, Vol. 29, Núm. 2, pp. 247-253
-
Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway
Oncotarget, Vol. 7, Núm. 19, pp. 28086-28095
-
HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
BMC Cancer, Vol. 16, Núm. 1
-
Handbook of HER2-targeted agents in breast cancer
Springer International Publishing, pp. 1-110